ISSN: 2148-8274 / E-ISSN: 2587-0084
, Türk Üreme Tıbbı ve Cerrahisi
Dergisi

Turkish Journal of Reproductive Medicine and Surgery

Dernek Sitesi
Kayıtlı İndexler
DERLEMELER

PrematürOvaryen Yetmezlik Tanımı, Etiyolojisi ve Hastaya Yaklaşım
Premature Ovarian Failure Definition, Etiology And Approach to the Patient
Received Date : 08 Dec 2020
Accepted Date : 29 Jan 2021
Available Online : 23 Feb 2021
Doi: 10.24074/tjrms.2020-80474 - Makale Dili: TR
TJRMS. 2021;5(1):23-31
ÖZET
Prematür ovaryen yetmezlik, kadınlarda 40 yaşından önce gonadotropin yüksekliğine, düşük östrojen seviyesinin eşlik ettiği erken ovaryen fonksiyon kaybıdır. Prematür ovaryen yetmezlik, genelde, daha önce düzenli olan menstrüel sikluslarda düzensizleşme ile kendini gösterir. Prematür ovaryen yetmezliğin etiyolojisinde, iyatrojenik, enfeksiyöz, otoimmün, genetik nedenler ve çevresel faktörler yer almaktadır.Hastalarda, kendi yaş grubundaki kontrollerle kıyaslandığında, kardiyovasküler hastalık, inme ve osteoporoz görülme riski artmıştır. Prematür ovaryen yetmezlik tanısı konduktan sonra, hasta, hassas ve özenli bir şekilde bilgilendirilmeli ve duygusal destek için uygun kaynaklara yönlendirilmelidir. Hastaya, geçici remisyon ve spontan gebelik gibi ihtimaller anlatılmalıdır. Prematür ovaryen yetmezlik şüphesi olan hastaların, mevcut olabilecek ek hastalıklar açısından multisistemik olarak değerlendirilmesi gerekmektedir.Tedavi için, uygun estrojen ve progesteron replasmanı yapılmalıdır. Prematür ovaryen yetmezliğin fiziksel ve sosyal etkilerinin yarattığı zorluklar nedeni ile bu tanıyı alan kadınların ayrıntılı olarak tetkik edilmesi veher kadın için tedavinin bireyselleştirilmesi son derece önemlidir.
ABSTRACT
Premature ovarian failure is early loss of ovarian function in women before age 40, accompanied by high gonadotropin and low estrogen levels. It's usually manifested by irregularity in previously regular menstrual cycles. Iatrogenic, infectious, autoimmune, genetic, environmental factors are involved in etiology of the disease. Patients have increased risk of cardiovascular disease, stroke, osteoporosis compared to controls in their age group. After the diagnosis, the patient should be informed precisely and attentively, directed to appropriate resources for emotional support. Possibilities such as transient remission and spontaneous pregnancy should be explained to patient. Patients with suspected disease should be evaluated multisystemically in terms of additional diseases that may be present. For treatment, appropriate estrogen and progesterone replacement should be done. Due to difficulties caused by physical, social effects of the disease, it’s extremely important to examine women who have this diagnosis in detail and to individualize the treatment for each woman.
SITE.TEXT.RESOURCES
  1. Gleicher N, Weghofer A, Oktay K, Barad D. Do Etiologies Of Premature Ovarian Aging (POA) Mimic Those Of Premature Ovarian Failure (POF)? Hum Reprod. 2009;24(10):2395-400. [Crossref]  [PubMed] 
  2. Grossmann B, Saur S, Rall K, Pecher A, Hübner S, Henes J, et al. Prevalence Of Autoimmune Disease in Women With Premature Ovarian Failure. 2020;5187.
  3. Edwards RG, Brod SA. Principals And Practice Of Assisted Human Reproduction. Philadelphia: W.B. Saunders; 1995. p.163-71.
  4. Nelson LM. Primary ovarian insufficiency, New England Journal of Medicine. 2009;360(6): 606-14. [Crossref]  [PubMed]  [PMC] 
  5. Ford EA, Beckett EL, Roman SD, McLaughlin EA, Sutherland JM. Advances in human primordial follicle activation and premature ovarian insufficiency. Reproduction. 2020;159(1): R15-R29. [Crossref]  [PubMed] 
  6. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744): 911-21. [Crossref] 
  7. Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, et al. Development of Luteinized Graafian Follicles in Patients with Karyotypically Normal Spontaneous Premature Ovarian Failure. The Journal of Clinical Endocrinology & Metabolism. 1994;79(5): 1470-5. [Crossref]  [PubMed] 
  8. Rebar RW, Connolly HV. Clinical Features of Young Women with Hypergonadotropic Amenorrhea. Obstetrical & Gynecological Survey. 1990;45(11):763-4. [Crossref] 
  9. Panay N, Kalu E. Management of Premature Ovarian Failure. Best Practice & Research Clinical Obstetrics & Gynaecology. 2009;23(1):129-40. [Crossref]  [PubMed] 
  10. Nippita T, Baber R. Premature Ovarian Failure: a Review. Climacteric. 2007;10(1):11-22. [Crossref]  [PubMed] 
  11. Knauff EAH, Eijkemans MJC, Lambalk CB, ten Kate-Booij MJ, HoPek A, Beerendonk CCM, et al. Anti-Mullerian Hormone, İnhibin B, And Antral Follicle Count in Young Women With Ovarian Failure. J Clin Endocrinol Metab. 2009;94(3):786-92. [Crossref]  [PubMed] 
  12. He C, Kraft P, Chen C, Buring JE, -Paré G, Hankinson SE, et al. Genome-Wide Association Studies İdentify Loci Associated with Age at Menarche and Age at Natural Menopause. Nature Genetics. 2009;41(6): 724-8. [Crossref]  [PubMed]  [PMC] 
  13. Perry JR, Stolk L, Franceschini N, Lunetta KL, Zhai G, McArdle PF, et al. Meta-analysis of Genome-wide Association Data İdentifies Two Loci İnfluencing Age at Menarche. Nature Genetics. 2009;41(6):648-50. [Crossref]  [PubMed]  [PMC] 
  14. Fassnacht W, Mempel A, Strowitzki T, Vogt P. Premature Ovarian Failure (POF) Syndrome: Towards the Molecular Clinical Analysis of İts Genetic Complexity. Current Medicinal Chemistry. 2006;13(12):1397-410. [Crossref]  [PubMed] 
  15. Persani L, Rossetti R, Cacciatore C. Genesİnvolved in Human Premature Ovarian Failure. Journal of molecular endocrinology. 2010;45(5):257-79. [Crossref]  [PubMed] 
  16. Cheng DH, Tan YQ, Di YF, Li LY, Lu GX. Crypt Y Chromosome Fragment Resulting From an X; Y Translocation in a Patient with Premature Ovarian Failure. Fertility and Sterility. 2009;92(2):828. e823-828. e826. [Crossref]  [PubMed] 
  17. Gravholt CH, et al. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017;177:G1-G70. [Crossref] 
  18. Schlessinger D, Herrera L, Crisponi L, Mumm S, Percesepe A, Pellegrini M, et al. Genes And Translocations İnvolved in POF. Am J Med Genet. 2002;111(3):328-33. [Crossref]  [PubMed] 
  19. Crowley WF. Pathogenesis And Causes Of Spontaneous Primary Ovarian İnsufficiency (Premature Ovarian Failure). 2020;1-22.
  20. Loutradis D, Patsoula E, Stefanidis K, Drakakis P, Antonakis G, Bletsa R, et al. Follicle-Stimulating Hormone Receptor Gene Mutations Are Not Evident in Greek Women with Premature Ovarian Failure and Poor Responders. Gynecologic and Obstetric İnvestigation. 2006;61(1):56-60. [Crossref]  [PubMed] 
  21. Sherman SL. Premature Ovarian Failure in The Fragile X Syndrome. American Journal of Medical Genetics. 2000;97(3):189-94. [Crossref] 
  22. Bennett CE, Conway GS, Macpherson JN, Jacobs PA, Murray A. Intermediate Sized CGG Repeats Are Not a Common Cause of İdiopathic Premature Ovarian Failure. Human Reproduction. 2010;25(5):1335-8. [Crossref]  [PubMed]  [PMC] 
  23. Welt CK. Primary Ovarian İnsufficiency: a More Accurate Term for Premature Ovarian Failure. Clinical Endocrinology. 2008;68(4): 499-509. [Crossref]  [PubMed] 
  24. Bussani C, Papi L, Sestini R, Baldinotti F, Bucciantini S, Bruni V, et al. Premature Ovarian Failure and Fragile X Premutation: a Study on 45 Women. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2004;112(2):189-91. [Crossref]  [PubMed] 
  25. Knauff EA, Richardus R, Eijkemans MJ, Broekmans FJ, de Jong FJ, Fauser BC, et al. Heterozygosity For The Classical Galactosemia Mutation Does Not Affect Ovarian Reserve And Menopausal Age. Reprod Sci. 2007;14(8):780-5. [Crossref]  [PubMed] 
  26. Tachdjian G, Aboura A, Portnoï MF, Pasquier M, Bourcigaux N, Simon T, et al. Cryptic Xp Duplication İncluding the SHOX Gene in a Woman with 46, X, del (X)(q21. 31) And Premature Ovarian Failure. Human Reproduction. 2008;23(1):222-6. [Crossref]  [PubMed] 
  27. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic Ovarian Failure Associated With An İnherited Mutation Of Human Bone Morphogenetic Protein-15 (BMP15) Gene. Am J Hum Genet. 2004;75(1):106-11. [Crossref]  [PubMed]  [PMC] 
  28. Di Pasquale E, Rossetti R, Marozzi A, Bodega B, Borgato S, Cavallo L, et al. Identification Of New Variants Of Human BMP15 Gene İn A Large Cohort Of Women with Premature Ovarian Failure. The Journal of Clinical Endocrinology &Metabolism. 2006;91(5):1976-9. [Crossref]  [PubMed] 
  29. Luborsky J, Meyer P, Sowers M, Gold E, Santoro N. Premature Menopause in a Multiethnic Population Study of the Menopause Transition. Human Reproduction. 2003;18(1): 199-206. [Crossref]  [PubMed] 
  30. Fierabracci A, Bizzarri C, Palma A, Milillo A, Bellacchio E, Cappa M. A Novel Heterozygous Mutation of The AIRE Gene in a Patient with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Syndrome (APECED). Gene. 2012;511(1):113-7. [Crossref]  [PubMed] 
  31. Simpson JL. Genetic and Phenotypic Heterogeneity in Ovarian Failure. Annals of the New York Academy of Sciences. 2008;1135(1): 146-54. [Crossref]  [PubMed] 
  32. Crisponi L, Deiana M, Loi A, Chiappe F, Uda M, Amati P, et al. The Putative Forkhead Transcription Factor FOXL2 is Mutated in Blepharophimosis/Ptosis/ Epicanthus İnversus Syndrome. Nat Genet. 2001;27(2):159-66. [Crossref]  [PubMed] 
  33. Raile K, Stobbe H, Tröbs RB, Kiess W, Pfäffle R. A New Heterozygous Mutation Of The FOXL2 Gene is Associated With A Large Ovarian Cyst And Ovarian Dysfunction in An Adolescent Girl With Blepharophimosis/Ptosis/Epicanthus İnversus Syndrome. Eur J Endocrinol. 2005;153(3):353-8. [Crossref]  [PubMed] 
  34. Settas N, Anapliotou M, Kanavakis E, Fryssira H, Sofocleous C, Dacou-Voutetakis C, et al. A Novel FOXL2 Gene Mutation And BMP15 Variants in A Woman With Primary Ovarian İnsufficiency And Blepharophimosis-Ptosis-Epicanthus İnversus Syndrome. Menopause. 2015;22(11):1264-8. [Crossref]  [PubMed] 
  35. Pagnamenta AT, Taanman JW, Wilson CJ, Anderson NE, Marotta R, Duncan AJ, et al. Dominant İnheritance of Premature Ovarian Failure Associated With Mutant Mitochondrial DNA Polymerase Gamma. Hum Reprod. 2006;21(10):2467-73. [Crossref]  [PubMed] 
  36. Jenkinson EM, Clayton-Smith J, Mehta S, Bennett C, Reardon W, Green A, et al. PerraultSsyndrome: Further Evidence For Genetic Heterogeneity. Journal of neurology. 2012;259:974-6. [Crossref]  [PubMed] 
  37. Doldi N, Belvisi L, Bassan M, Fusi F, Ferrari A. Premature Ovarian Failure: Steroid Synthesis and Autoimmunity. Gynecological Endocrinology. 1998;12(1):23-8. [Crossref]  [PubMed] 
  38. Hoek A, Schoemaker J, Drexhage H. Premature Ovarian Failure and Ovarian Autoimmunity 1. Endocrine Reviews. 1997;18(1):107-34. [Crossref]  [PubMed] 
  39. Khole V. Does Ovarian Autoimmunity Play a Role in the Pathophysiology of Premature Ovarian İnsufficiency? Journal of Mid-Life Health. 2010;1(1): 9. [Crossref]  [PubMed]  [PMC] 
  40. Bakalov V, Vanderhoof V, Bondy C, Nelson L. Adrenal Antibodies Detect Asymptomatic Auto-İmmune Adrenal İnsufficiency in Young Women with Spontaneous Premature Ovarian Failure. Human Reproduction. 2002;17(8): 2096-100. [Crossref]  [PubMed] 
  41. Sharara FI, Seifer DB, Flaws JA. Environmental Toxicants and Female Reproduction. Fertility and Sterility. 1998;70(4):613-22. [Crossref] 
  42. Anasti JN. Premature Ovarian Failure: An Update. Fertility and Sterility. 1998;70(1):1-15. [Crossref] 
  43. Cox L, Liu JH. Primary Ovarian İnsufficiency: an Update. International Journal of Women's Health. 2013;6:235-43. [Crossref]  [PubMed]  [PMC] 
  44. Familiari U, Larocca L, Tamburrini E, Antinori A, Ortona L, Capelll A. Premenopausal Cytomegalovirus Oophoritis in a Patient with AIDS. Aids. 1991;5(4):458. [Crossref]  [PubMed] 
  45. Wallace WH, Anderson RA, Irvine DS. Fertility Preservation For Young Patients with Cancer: Who is At Risk and What Can Be Offered? The Lancet Oncology. 2005;6(4):209-18. [Crossref] 
  46. Davis VJ. Female Gamete Preservation, Cancer. 2006;107(S7):1690-4. [Crossref]  [PubMed] 
  47. Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of Cancer Treatment on Ovarian Function, Fertility and Sterility. 2009;92(2):417-27. [Crossref]  [PubMed] 
  48. Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D. Ovarian Transposition for Patients with Cervical Carcinoma Treated by Radiosurgical Combination. Fertility and Sterility. 2000;74(4):743-8. [Crossref] 
  49. Vermeulen A. Environment, Human Reproduction, Menopause, and Andropause. Environmental Health Perspectives. 1993;101(2): 91. [Crossref]  [PubMed]  [PMC] 
  50. Mark-Kappeler CJ, Hoyer PB, Devine PJ. Xenobiotic Effects on Ovarian Preantral Follicles. Biology of Reproduction. 2011;85(5): 871-83. [Crossref]  [PubMed]  [PMC] 
  51. Pouresmaeili F, Fazeli Z. Premature Ovarian Failure: a Critical Condition in the Reproductive Potential with Various Genetic Causes. Int J Fertil Steril. 2014;8(1):1-12.
  52. Alici-Davutoglu E, Akhan S, Bastu E, Gungor-Ugurlucan F, Iyibozkurt AC, Topuz S. Impact of Premature Ovarian Failure and Hormone Replacement Therapy on Androgens and Bone Mineral Density in Caryotypically Normal (46,XX) Patients. Minerva Ortopedica e Traumatologica. 2013;64(1):89-96.
  53. Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. Meeting the Needs of Young Women with Secondary Amenorrhea and Spontaneous Premature Ovarian Failure. Obstetrics & Gynecology. 2002;99(5 Part 1): 720-5. [Crossref]  [PubMed] 
  54. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13(2):265-79. [Crossref]  [PubMed] 
  55. Groff AA, Covington SN, Halverson LR, Fitzgerald OR, Vanderhoof V, Calis K, et al. Assessing The Emotional Needs Of Women With Spontaneous Premature Ovarian Failure. Fertil Steril. 2005;83(6):1734-41. [Crossref]  [PubMed] 
  56. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature Menopause or Early Menopause: Long-Term Health Consequences. Maturitas. 2010;65(2): 161-6. [Crossref]  [PubMed]  [PMC] 
  57. Tao X, Zuo A, Wang J, Tao F. Effect Of Primary Ovarian İnsufficiency and Early Natural Menopause on Mortality: a Meta-analysis, Climacteric. 2016;19(1):27-36. [Crossref]  [PubMed] 
  58. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-Term Health Consequences of Premature or Early Menopause and Considerations For Management. Climacteric. 2015;18(4):483-91. [Crossref]  [PubMed]  [PMC] 
  59. Maclaran K, Horner E, Panay N. Premature Ovarian Failure: Long-Term Sequelae. Menopause International. 2010;16(1):38-41. [Crossref]  [PubMed] 
  60. Schmidt PJ, Cardoso GM, Ross JL, Haq N, Rubinow DR, Bondy CA. Shyness, Social Anxiety, and İmpaired Self-esteem in Turner Syndrome and Premature Ovarian failure. Jama. 2006;295(12):1373-8. [Crossref]  [PubMed] 
  61. Ryan J, Scali J, Carrière I, Amieva H, Rouaud O, Berr C, et al. Impact Of a Premature Menopause on Cognitive Function in Later Life. BJOG. 2014;121(13):1729-39. [Crossref]  [PubMed] 
  62. Mann E, Singer D, Pitkin J, Panay N, Hunter MS. Psychosocial Adjustment in Women With Premature Menopause: a Cross-sectioal Survey. Climacteric. 2012;15(5):481-9. [Crossref]  [PubMed] 
  63. Committee Opinion no. 605: Primary Ovarian İnsufficiency in Adolescents and Young Women. Obstet Gynecol. 2014;124(1):193-7. [Crossref]  [PubMed] 
  64. Shannon D, Sullivan MD. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause, Fertil Steril. 2016;106(7):1588-99. [Crossref]  [PubMed]  [PMC] 
  65. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-32. [Crossref] 
  66. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas. 1999;32: 161-70. [Crossref] 
  67. Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf). 2010;73:707-14. [Crossref]  [PubMed] 
  68. Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomised controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab. 2016;jc20154063. [Crossref]  [PubMed] 
  69. McNeil M. Menopausal Hormone Therapy: Understanding Long-term Risks and Benefits. Jama. 2017;318(10):911-3. [Crossref]  [PubMed] 
  70. Donnez J, Dolmans MM. Natural hormone replacement therapy with a functioning ovary after the menopause: dream or reality? Reprod Biomed Online. 2018;37(3):359-66. [Crossref]  [PubMed] 
  71. Donnez J, Dolmans MM. The ovary: from conception to death. Fertil Steril. 2017;108(4): 594-5. [Crossref]  [PubMed] 
  72. Kolibianakia EE, Goulisb DG, Kolibianakisc EM. Ovarian tissue cryopreservation and transplantation to delay menopause: facts and fiction. Maturitas. 2020;142:64-7. [Crossref]  [PubMed] 
  73. Vuković P, Kasum M, Orešković D, Čehić E, Raguž J, Elezaj S, et al. Importance of ovarian tissue cryopreservation in fertility preservation and anti-aging treatment. Gynecol Endocrinol. 2019;35(11):919-23. [Crossref]  [PubMed]